<unk> , also known as Kanzaki disease and alpha-N-acetylgalactosaminidase deficiency is a rare congenital metabolic disorder in humans. This lysosomal storage disorder is caused by  a deficiency in the enzyme alpha-NAGA alpha-N-acetylgalactosaminidase, attributable to mutations in the NAGA gene on chromosome 22, which leads to excessive lysosomal accumulation of glycoproteins. A deficiency of the alpha-NAGA enzyme leads to an accumulation of glycosphingolipids throughout the body. This accumulation of sugars gives rise to the clinical features associated with this disorder.<unk>  is an autosomal recessive disorder, meaning that one must inherit an abnormal allele from both parents in order to have the disease.
There are three main types of the disease each with its own distinctive symptoms.
In the Type I infantile form, infants will develop normally until about a year old. At this time, the affected infant will begin to lose previously acquired skills involving the coordination of physical and mental behaviors. Additional neurological and neuromuscular symptoms such as diminished muscle tone, weakness, involuntary rapid eye movements, vision loss, and seizures may become present. With time, the symptoms worsen and children affected with this disorder will experience a decreased ability to move certain muscles due to muscle rigidity. The ability to respond to external stimuli will also decrease.  Other symptoms include neuroaxonal dystrophy from birth, discoloration of skin, Telangiectasia or widening of blood vessels.
In Type II adult form, symptoms are milder and may not appear until the individual is in his or her 30s. Angiokeratomas, an increased coarsening of facial features, and mild intellectual impairment are likely symptoms.
Type III is considered an intermediate disorder.  Symptoms vary and can include to be more severe with seizures and mental retardation, or less severe with delayed speech, a mild autistic like presentation, and/or behavioral problems.
Infants with<unk>  tend to die within 4 years of birth, therefore, treatment for this form of the disease is mostly palliative. However, Type II<unk> , with its late onset of symptoms, is not characterized by neurological degeneration. There is no known cure for<unk> , but bone marrow transplants have been trialed, as they have been successful in curing other glycoprotein disorders.
Amniocentesis or chorionic villus sampling can be used to screen for the disease before birth. After birth, urine tests, along with blood tests and skin biopsies can be used to diagnose<unk> . Genetic testing is also always an option, since different forms of<unk>  have been mapped to the same gene on chromosome 22; though different changes (mutations) of this gene are responsible for the infantile- and adult-onset forms of the disease.<unk>  was named after Detlev<unk>  (1946- ) M.D., the first author of a 1988 paper detailing the disease. It also named after the Japanese Biochemist and Physician, Hiro Kanzaki (1949- ), who further studied it and released papers detailing the disease in 2006.[citation needed]
Schindler disease
Kummell disease
Gunther disease
Borna disease
Haff disease
Gonochorism
Rhizomelic chondrodysplasia punctata
Aguecheek disease